(SMMT) Summit Therapeutics - Overview
Stock: Ivonescimab, Bispecific Antibody, Anti-Pd-1, Anti-Angiogenic
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 106% |
| Relative Tail Risk | -20.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.11 |
| Alpha | -56.85 |
| Character TTM | |
|---|---|
| Beta | 1.516 |
| Beta Downside | 0.156 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.98% |
| CAGR/Max DD | 0.89 |
Description: SMMT Summit Therapeutics January 03, 2026
Summit Therapeutics PLC (NASDAQ:SMMT) is a U.S.-based biopharma focused on developing “patient-friendly” medicines, with its flagship asset ivonescimab-a bispecific antibody that simultaneously blocks PD-1 and anti-angiogenic pathways-currently in Phase III trials for non-small cell lung cancer (NSCLC). The company was founded in 2003 and operates out of Miami, Florida.
**Key quantitative snapshot (as of the most recent public filings, Q3 2024):** market capitalization ≈ $120 million, cash & cash equivalents ≈ $45 million, and a cash-burn rate of roughly $8 million per quarter, implying ~5-6 months of runway absent additional financing. The Phase III trial has enrolled > 800 patients, with interim data (presented at ASCO 2024) suggesting a 22 % improvement in progression-free survival versus standard of care, though the full statistical significance remains pending.
**Sector context:** Immuno-oncology continues to outpace broader biotech growth, with global sales projected to exceed $150 billion by 2028 (CAGR ≈ 12 %). However, the market is increasingly sensitive to trial outcomes and pricing pressures, especially for bispecific antibodies that command premium pricing but also face heightened regulatory scrutiny.
**Risk considerations:** The company’s valuation hinges heavily on a single late-stage asset; any adverse safety signal or failure to meet primary endpoints would materially impair cash flow and could trigger dilution through a rights offering. Conversely, a positive readout could unlock partnership or acquisition interest, potentially expanding the cash runway.
For a deeper, data-driven look at SMMT’s valuation metrics and scenario analysis, the ValueRay research hub offers a concise, model-based overview.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.14 > 0.02 and ΔFCF/TA -91.61 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.14 > 3% & CFO -297.9m > Net Income -587.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (744.4m) vs 12m ago 2.45% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev -0.05%; Δ 0.05% > 0%) |
| Interest Coverage Ratio: -39.5k > 6 (EBITDA TTM -355.8m / Interest Expense TTM 9000 ) |
Altman Z'' -15.00
| A: 0.69 (Total Current Assets 246.5m - Total Current Liabilities 64.9m) / Total Assets 261.7m |
| B: -7.93 (Retained Earnings -2.07b / Total Assets 261.7m) |
| C: -0.93 (EBIT TTM -355.8m / Avg Total Assets 382.3m) |
| D: -29.87 (Book Value of Equity -2.07b / Total Liabilities 69.5m) |
| Altman-Z'' Score: -58.91 = D |
What is the price of SMMT shares?
Over the past week, the price has changed by -11.34%, over one month by -13.39%, over three months by -17.47% and over the past year by -28.84%.
Is SMMT a buy, sell or hold?
- StrongBuy: 7
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SMMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.5 | 117.5% |
| Analysts Target Price | 33.5 | 117.5% |
| ValueRay Target Price | 17.7 | 14.9% |
SMMT Fundamental Data Overview January 30, 2026
P/B = 60.4807
Revenue TTM = 0.0 USD
EBIT TTM = -355.8m USD
EBITDA TTM = -355.8m USD
Long Term Debt = 5.43m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.77m USD (from shortTermDebt, last fiscal year)
Debt = 7.22m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -97.6m USD (from netDebt column, last fiscal year)
Enterprise Value = 11.41b USD (11.64b + Debt 7.22m - CCE 238.6m)
Interest Coverage Ratio = -39.5k (Ebit TTM -355.8m / Interest Expense TTM 9000 )
EV/FCF = -38.23x (Enterprise Value 11.41b / FCF TTM -298.5m)
FCF Yield = -2.62% (FCF TTM -298.5m / Enterprise Value 11.41b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 15.0m) / Revenue TTM)
Tobins Q-Ratio = 43.60 (Enterprise Value 11.41b / Total Assets 261.7m)
Interest Expense / Debt = 0.12% (Interest Expense 9000 / Debt 7.22m)
Taxrate = 21.0% (US default 21%)
NOPAT = -281.1m (EBIT -355.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.80 (Total Current Assets 246.5m / Total Current Liabilities 64.9m)
Debt / Equity = 0.04 (Debt 7.22m / totalStockholderEquity, last quarter 192.3m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -97.6m / EBITDA -355.8m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -97.6m / FCF TTM -298.5m)
Total Stockholder Equity = 279.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -153.7% (out of range, set to none)
RoE = -210.3% (Net Income TTM -587.7m / Total Stockholder Equity 279.4m)
RoCE = -124.9% (out of range, set to none) (EBIT -355.8m / Capital Employed (Equity 279.4m + L.T.Debt 5.43m))
RoIC = -94.89% (negative operating profit) (NOPAT -281.1m / Invested Capital 296.2m)
WACC = 11.49% (E(11.64b)/V(11.65b) * Re(11.50%) + D(7.22m)/V(11.65b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.00%
Fair Price DCF = unknown (Cash Flow -298.5m)
EPS Correlation: 25.14 | EPS CAGR: 4.53% | SUE: 3.91 | # QB: 1
Revenue Correlation: -63.90 | Revenue CAGR: -16.48% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=-0.035 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.74 | Chg30d=+0.001 | Revisions Net=-1 | Growth EPS=+2.7% | Growth Revenue=-96.9%